Recommendations for Timely Access to ATMPs in Europe

This report provides an overview of the characteristics and benefits of Advanced Therapy Medicinal Products (ATMPs), and the current regulatory market and access frameworks in six European countries: France, Germany, Italy, Spain, Sweden, and the United Kingdom. It also identifies hurdles to adoption and makes EU-wide policy recommendations to address those challenges.

The Alliance for Regenerative Medicine (ARM) is the preeminent global advocate for regenerative and advanced therapies. ARM fosters research, development, investment, and commercialization of transformational treatments and cures for patients worldwide.